Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00663793 · ClinicalTrials.gov registry record · Phase 1

ORAL T-6: Oral Androgens in Man-6

A Phase 1 study of Contraception and Hypogonadism, sponsored by University of Washington.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT00663793 is a Phase 1 study of Contraception and Hypogonadism that has completed, run by University of Washington. The registered enrollment target is 16 participants, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00663793, a Phase 1 study of Contraception and Hypogonadism, has completed, sponsored by University of Washington.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

We propose a study to determine the single-dose pharmacokinetics of these two novel formulations of testosterone in normal men with experimentally induced hypogonadism.

Interventions

  • DRUG Finasteride
  • DRUG Testosterone
  • DRUG Acyline

Study Locations (1)

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2008-10
Est. Completion 2009-06
Phase Phase 1

Sponsor

University of Washington

1,048 total trials

What the Registry Record Tells You About NCT00663793

The ClinicalTrials.gov registry entry for NCT00663793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (96% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Contraception appearing as the primary indexed condition, and to 3 interventions - of which Finasteride is the first listed.

NCT00663793 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00663793 about?

NCT00663793 is a clinical study titled "ORAL T-6: Oral Androgens in Man-6". We propose a study to determine the single-dose pharmacokinetics of these two novel formulations of testosterone in normal men with experimentally induced hypogonadism.

What is the current status of trial NCT00663793?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2008-10. Estimated completion is 2009-06.

What conditions does trial NCT00663793 study?

This clinical trial studies the following conditions: Contraception, Hypogonadism.

What interventions are being tested in trial NCT00663793?

The interventions under investigation include: Finasteride (DRUG), Testosterone (DRUG), Acyline (DRUG).

Who is sponsoring clinical trial NCT00663793?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00663793 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Contraception

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.